Vertex Pharmaceuticals Incorporated (VRTX) Citi Annual Global Healthcare Conference 2025 December 3, 2025 9:00 AM EST
Company Participants
Charles Wagner – Executive VP, COO & CFO
David Altshuler – Executive VP & Chief Scientific Officer
Conference Call Participants
Geoffrey Meacham – Citigroup Inc., Research Division
Presentation
Geoffrey Meacham
Citigroup Inc., Research Division
Welcome to the second day of the Citi Global Healthcare Conference. My name is Geoff Meacham. I’m the senior biopharma analyst. And we’re thrilled today to have Vertex Pharmaceuticals. And on stage with me, we have Charlie Wagner, Chief Operation and Financial Officer; we have David Altshuler, who is EVP and CSO and maybe 6 months from retirement. Okay. So both legends. So guys, thanks for joining.
Charles Wagner
Executive VP, COO & CFO
One legend. I’m aspiring.
David Altshuler
Executive VP & Chief Scientific Officer
You shouldn’t say that about yourself, Charlie.
Question-and-Answer Session
Geoffrey Meacham
Citigroup Inc., Research Division
Let’s talk first about JOURNAVX, maybe commercial and then move over to clinical. So maybe, Charlie, just give us a bit of a status update with the launch in acute pain, are you guys comfortable with the number of centers, states, institutions looking to next year? Are there — is there more progress to be gained and we can get into some of the specifics.
Charles Wagner
Executive VP, COO & CFO
Yes, sure thing. Yes, honestly, it’s been a terrific year for this launch. It’s a significant launch for us, and we feel really great about the progress that we’ve made so far. Coming into the year, we had 3 primary goals. One was ensuring broad access with payers, ensuring hospital and health care system access and then also having kind of a terrific first year seamless experience for physicians and patients. And I think we’ve made great progress on all of that.
Read the full article here